Venom induced pressure elevation reversible syndrome: a severe pediatric rattlesnake envenomation, evidence for conservative management, and call for naming the syndromeVenom induced pressure elevation reversible syndrome: a severe pediatric rattlesnake envenomation, evidence for conservative management, and call for naming the syndrome

Posted by
  Venom induced pressure elevation reversible syndrome: a severe pediatric rattlesnake envenomation, evidence for conservative management, and call for naming the syndromeVenom induced pressure elevation reversible syndrome: a severe pediatric rattlesnake envenomation, evidence for conservative management, and call for naming the syndrome Abstract Introduction : Rattlesnake envenomation frequently mimics traumatic compartment syndrome, as both are characterized by severe pain, swelling, and elevated compartment pressures. Unlike traumatic compartment syndrome there have been no documented cases of ischemic limb injury after envenomated patients have received antivenom. Furthermore, there is experimental evidence that fasciotomy worsens myonecrosis. This has led medical toxicologists and surgical guidelines to shift from liberally recommending fasciotomy to near universal recommendation of antivenom alone. Despite this, fasciotomies continue to be recommended and performed on rattle...

Advancements in Antivenom Therapy: Historical Perspectives, Current Challenges, and Ongoing Clinical Trials

Posted by

 



Advancements in Antivenom Therapy: Historical Perspectives, Current Challenges, and Ongoing Clinical Trials

Abstract

Snakebite envenomation remains a severe global health burden, particularly in impoverished, rural, and tropical regions where healthcare resources are sparse. Despite over 125 years of progress in antivenom therapy, numerous obstacles persist related to efficacy, specificity, cost, and availability. Conventional antivenoms, although life-saving, are associated with significant drawbacks, including species specificity and adverse immunologic reactions. This review explores the historical milestones in antivenom development, discusses present therapeutic limitations, highlights novel innovations through biotechnological approaches, and presents a list of ongoing clinical trials that aim to revolutionize the field. It emphasizes the pressing need for improved therapeutics and the critical role of translational research in mitigating the global impact of snakebite envenomation. 

Citation: Luis A. Roque. Advancements in antivenom therapy: Historical perspectives, current challenges, and ongoing clinical trials. Innovative Medicines & Omics 2025, 2(3), 13–20. https://doi.org/10.36922/IMO025240026

Roque, L. A. (2025). Advancements in antivenom therapy: Historical perspectives, current challenges, and ongoing clinical trials. Innovative Medicines & Omics, 2(3), 13–20. https://doi.org/10.36922/IMO025240026

PDF: Advancements in antivenom therapy: Historical perspectives, current challenges, and ongoing clinical trials: https://api-journal.accscience.com/journal/article/preview?doi=10.36922/IMO025240026